Our consultancy provides strategic direction and tactical execution for development of novel pharmaceuticals and medical devices
Medical product development is a complex, expensive, risky venture. How does one get from early findings to an approved product? How do you get to the key milestones as rapidly and efficiently as possible?
Gary Novack, Ph.D.
Gary D. Novack, Ph.D., President of PharmaLogic Development, Inc. has decades of experience in successful product development. Together with his team of senior experts, PharmaLogic can help you execute that plan.
In our 25+ years working in manifold therapeutic areas with pharmaceuticals, biologics and devices, the firm’s particular expertise is in local therapy (ophthalmology and dermatology).
Based upon decades of successful product development experience, PharmaLogic Development, Inc., can help you develop and execute a strategic plan for your product. Working in manifold therapeutic areas with pharmaceuticals, biologics and devices, our expertise is in local therapy (ophthalmology and dermatology).
Dr. Novack states “The more I work in the development of new pharmaceuticals, the more I see that early development is a complex interaction of pharmaceutics (formulation), safety assessment (local and systemic), and clinical planning. Not only do we help plan and execute what needs to be done, but what needs to be done when.”
Many of his experiences and unique perspectives in product development may be found in the over two dozen editorials he has written as a contributing editor to The Ocular Surface.
If you don’t know where you are going, any road will get you there.
– Lewis Carroll
My article with Michele Lim MD is listed first in the American Journal of Ophthalmology, December 2019 issue. This was my personal patient's view of retinal detachment, including my atypical presentation of symptoms. Colleague Dr. Lim added a perspective on...read more
Dr. Novack returned to the University of Wisconsin to present in the Department of Ophthalmology Grand Rounds. His spoke about what it would take to develop a drug to prevent the development of myopia (nearsightedness) in children. Myopia has reached epidemic...read more
Academic journals have long worked on the "subscription model", where print subscribers pay to read articles that, for the most part, authors submit for free. With the advent of digital content, the same model has been used - subscribers pay and author provide...read more